Article citationsMore>>
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wisniowski, M. Siolek, R. Dent, J. Lubinski and S. Narod, “Pathologic Complete Response Rates in Young Women with BRCA1-Positive Breast Cancers after Neoadjuvant Chemotherapy,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, Vol. 28, No. 3, 2010, pp. 375-379. doi:10.1200/JCO.2008.20.7019
has been cited by the following article:
-
TITLE:
Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer
AUTHORS:
Grazia Artioli, Giuseppe Azzarello, Fabrizio Meggiolaro, Jacopo Wabersich, Lucia Borgato, Mario Bari
KEYWORDS:
BRCA 2; Breast Cancer; DNA; Cisplatin; Taxane
JOURNAL NAME:
Advances in Breast Cancer Research,
Vol.2 No.3,
June
24,
2013
ABSTRACT:
Background: Metastatic
breast cancer in BRCA 2 patients is lacking of target therapy studies. Case: We
present a case of a 34-year-old woman affected by a recurrent metastatic breast cancer after 5 years
treated with weekly nab-paclitaxel and three weekly Cisplatin obtaining a radiological
complete response with 6 cycles. Conclusion: It is important to emphasize that patients with a
molecular disorder who selected for
“target” chemotherapy can obtain optimal
response rate. Exploiting the mechanism of action of DNA damage in our favor,
using cisplatin for example and basing on literature show the efficacy of using taxane in BRCA 2 patients, obtaining a very high
response rate.
Related Articles:
-
Jai Dev Chandel, Nand Lal Singh
-
Casimir Komenan
-
Daoling Fu, Ming Yang, Jindong Chang
-
Isaac Kim, Kwanbum Lee, Seung Ah Lee, Yeon Hee Park, Seung Ki Kim
-
Ezra Davar